PepGen Inc. (PEPG)
| Previous Close | 13.96 |
| Open | 14.08 |
| Bid | 13.37 x 100 |
| Ask | 14.49 x 100 |
| Day's Range | 13.87 - 14.15 |
| 52 Week Range | 3.72 - 17.51 |
| Volume | |
| Avg. Volume | 89,577 |
| Market Cap | 454.437M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.30 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.60 |
ZacksBest Momentum Stocks to Buy for April 25th
TXO, PEPG and ERO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 25, 2024.
GlobeNewswirePepGen to Participate in Upcoming Investor Conferences
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that management will participate in the following upcoming investor conferences: Stifel 2024 CNS Days (Virtual) Tuesday, March 19, 2024, at 1:00 p.m. ET, Fireside Chat Needham Annual Healthcare Conference (Virtual) Monda
- GlobeNewswire
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) granted both orphan drug and rare pediatric disease designations for PGN-EDO51, an investigational therapeutic for Duchenne muscular dystrophy (DMD) patients whose mutatio
